Gao-Kai Li
Research Subjects
Gao-Kai Li has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bing Bai
NHC Key Laboratory of Radiobiology
1 shared publication - Hai-Chen Wang
NHC Key Laboratory of Radiobiology
1 shared publication - Hai-Yan Qin
Department of Plastic Surgery
1 shared publication - Shilong Sun
NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130021, China
1 shared publication - Xue-Mei Fu
Jilin Women And Children Health Hospital
1 shared publication - Ying Liu
1 Department of Toxicology, School of Public Health, Jilin University, Changchun, China
1 shared publication
Latest Publications
- Open Access
- 29 August 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 7608712
Dysregulation of EZH2/miR‐138‐5p Axis Contributes to Radiosensitivity in Hepatocellular Carcinoma Cell by Downregulating Hypoxia‐Inducible Factor 1 Alpha (HIF‐1α)
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase involved in cell proliferation, invasion, angiogenesis, and metastasis in various cancers, including hepatocellular carcinoma (HCC). However, the role and molecular mechanisms of EZH2 in HCC radiosensitivity remain unclear. Here, we show that EZH2 is upregulated in HCC cells and the aberrantly overexpressed EZH2 is associated with the poor prognosis of HCC patients. Using miRNA databases, we identified miR‐138‐5p as a regulator of EZH2. We also found that miR‐138‐5p was suppressed by EZH2‐induced H3K27me3 in HCC cell lines. MiR‐138‐5p overexpression and EZH2 knockdown enhanced cellular radiosensitivity while inhibiting cell migration, invasion, and epithelial‐mesenchymal transition (EMT). Analysis of RNA‐seq datasets revealed that the hypoxia‐inducible factor‐1 (HIF‐1) signaling pathway was the main enrichment pathway for differential genes after miR‐138‐5p overexpression or EZH2 knockdown. Expression level of HIF‐1α was significantly suppressed after miR‐138‐5p overexpression or silencing of EZH2. HIF‐1α silencing mitigated resistance of HCC cells and inhibited EMT. This study establishes the EZH2/miR‐138‐5p/HIF‐1α as a potential therapeutic target for sensitizing HCC to radiotherapy.
- 29 August 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 7608712
Open AccessDysregulation of EZH2/miR‐138‐5p Axis Contributes to Radiosensitivity in Hepatocellular Carcinoma Cell by Downregulating Hypoxia‐Inducible Factor 1 Alpha (HIF‐1α)
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase involved in cell proliferation, invasion, angiogenesis, and metastasis in various cancers, including hepatocellular carcinoma (HCC). However, the role and molecular mechanisms of EZH2 in HCC radiosensitivity remain unclear. Here, we show that EZH2 is upregulated in HCC cells and the aberrantly overexpressed EZH2 is associated with the poor prognosis of HCC patients. Using miRNA databases, we identified miR‐138‐5p as a regulator of EZH2. We also found that miR‐138‐5p was suppressed by EZH2‐induced H3K27me3 in HCC cell lines. MiR‐138‐5p overexpression and EZH2 knockdown enhanced cellular radiosensitivity while inhibiting cell migration, invasion, and epithelial‐mesenchymal transition (EMT). Analysis of RNA‐seq datasets revealed that the hypoxia‐inducible factor‐1 (HIF‐1) signaling pathway was the main enrichment pathway for differential genes after miR‐138‐5p overexpression or EZH2 knockdown. Expression level of HIF‐1α was significantly suppressed after miR‐138‐5p overexpression or silencing of EZH2. HIF‐1α silencing mitigated resistance of HCC cells and inhibited EMT. This study establishes the EZH2/miR‐138‐5p/HIF‐1α as a potential therapeutic target for sensitizing HCC to radiotherapy.